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The last years, many studies reported associations between correlates of vitamin D exposure and several correlates of multiple
sclerosis (MS) disease activity. This review discusses studies on vitamin D status, Expanded Disability Status Scale (EDSS) score,
and relapse activity of MS. Furthermore, several considerations for intervention studies on vitamin D supplementation in MS are
provided.
Vitamin D is hot in multiple sclerosis (MS) research. The
geographical distribution of MS prevalence, which increases
when approaching the poles, sparked the interest in a poor
vitamin D exposure as a risk factor for developing MS [1].
Now, half a century of research further, a large body of
clinical observations and experimental work in vitro and in
animal models of MS has been reported [2]. As reviewed
recently, a limited exposure to sunlight and other correlates
of vitamin D exposure has been associated consistently with
an increased risk on developing MS [3]. The prospect of a
potential tool to prevent MS is tempting, yet challenging to
investigate in an intervention study since it would require
a huge population to measure any eﬀect on MS incidence.
However, vitamin D supplementation has not only been
proposedtopreventMS,butalsotoattenuatediseaseactivity
of MS [4].
In patients with established MS, earliest observations
show a seasonal ﬂuctuation of several disease characteristics.
In Switzerland, more relapses were recorded during winter
and spring than during summer [5]. More gadolinium
enhancing lesions on T1 MRI have been reported in
Germanyinspringandearlysummer,andlessinautumn[6].
Regrettably, these observations were not related directly to
serum concentrations of 25-hydroxyvitamin D (25(OH)D),
the vitamin D metabolite that reﬂects vitamin D status best
[7], and prove diﬃcult to reproduce. Other studies did cor-
relatemeasuresof MSseverity directly withvitamin D status.
The most widely used score to quantify disability due to MS
is the Expanded Disability Status Scale (EDSS) [8]. EDSS-
score has been reported to correlate negatively with serum
25(OH)D levels [9, 10]. Van der Mei et al. showed elegantly
that EDSS-score also correlated negatively with recent sun
exposure [10]. Therefore, it remains to be seen whether
vitamin D status contributes to disability progression in MS,
since(prospective)studiesonthisissueareatpresentlacking.
Interestingly, however, Burton et al. performed a small phase
I/II study which compared two groups of MS patients on
supplementation with either high (up to 40.000IU/d) or
low doses (≤4.000IU/d) of vitamin D3 for 52 weeks [11].
They reported a smaller proportion of patients with any
progression on the EDSS-scale in the high- versus low-
dose vitamin D group (2/25 versus 9/24, resp.). Although
premature, this ﬁnding encourages further research on the
eﬀect of vitamin D on disease progression of MS. Relapse
activity has also been related to vitamin D status. During
relapse, lower serum 25(OH)D levels have been reported in
several MS populations, when compared to remission of MS
[12–14]. However, also this information is prone to many
interpretations. We observed that patients with <5y e a r s
relapsing remitting MS (RRMS) and ≥1 relapses in the 22 Autoimmune Diseases
years prior to serum sampling had markedly lower serum
25(OH)D levels when compared to relapse-free patients [9].
Interestingly, a large prospective longitudinal study in RRMS
patients with a wider range of disease duration showed that
an increase of serum 25(OH)D levels with 10nmol/L was
associated with a 9–12% reduction of the hazard on relapses
[15]. Additionally, a prospective study in children with
RRMS calculated a comparable 14% decrease in hazard on
relapsesforeach10nmol/LincreaseofvitaminDstatus[16].
These studies suggest that supplementation with vitamin D
may protect RRMS patients against relapses. Interestingly,
although not statistically signiﬁcant, a smaller proportion of
patients with relapses was described by Burton et al. in the
high- versus low-dose vitamin D3 supplementation group
[11].
Altogether, the evidence that is available on vitamin
D status and disease activity of MS shows a consistent
picture. To consolidate a possible role of vitamin D sup-
plementation in the treatment of MS, randomized placebo-
controlledclinicaltrialsareneeded.Supplementationofhigh
doses of vitamin D could easily elevate serum 25(OH)D
levels with 100nmol/L [11, 17]. When a linear relationship
between vitamin D status and reduction of relapse-risk is
assumed [15], the eﬀect of this intervention on relapse-risk
could be substantial [15, 16]. However, there are several
considerations. First of all, vitamin D status predicts the
hazard on relapses, but vitamin D status itself is dependent
on sun exposure and outdoor physical activity. There is
some evidence available that both these factors contribute
individually to disease activity of MS [18]. Additionally, the
inverse linearity of the relationship between vitamin D status
and hazard for relapses in the supraphysiological range of
serum25(OH)Dlevelsisuncertain[15].Therefore,theeﬀect
in intervention studies may not be as large as predicted
from observational studies. Secondly, the amount of vitamin
D which should be supplemented is uncertain. In most
clinical trials with a new treatment, the diﬀerence between
presence and absence of a speciﬁc substance is compared.
In studies on vitamin D, an eﬀect of supraphysiological
versus physiological levels of vitamin D exposure will be
assessed. Supplementation of low doses may fail to reduce
the risk on relapses signiﬁcantly when compared to the
physiological range of vitamin D status in control groups.
This problem could be tackled by selective inclusion of
patients with a poor vitamin D status. Alternatively, high
doses of vitamin D could be supplemented. Although short-
term exposure to high doses of vitamin D showed no side-
eﬀects [11, 17], there are some concerns on long-term safety
and eﬃcacy. Thirdly, the groups of patients which should
be supplemented with vitamin D are ill deﬁned. The most
fundamental choice is the inclusion of either RRMS or
progressive MS patients. Progressive MS patients display
the poorest vitamin D status [9], yet an eﬀect of vitamin
D on EDSS progression is less well consolidated. Since an
eﬀect on relapse activity is most likely [15, 16], studies in
RRMS patients are most obvious. Mechanistic approaches
may also help to specify the patients to be included. We
showed that, in RRMS patients with a short disease duration
of <5 years, vitamin D status correlated with peripheral
T cell homeostasis [19]. Additionally, supplementation of
vitamin D reduced the T cell proliferative response to myelin
antigens in RRMS patients [11]. Alternatively, 25(OH)D is
also present in the central nervous system of MS patients
and may be involved in local immune regulatory systems
in progressive MS [20]. Fourthly, response of patients to
vitamin D supplementation may depend upon the genetic
proﬁle of both vitamin D-related genes [21] and MHC class
II genotype [22]. Intervention studies should allow analyses
on genetic proﬁles associated with response to vitamin D.
Lastly, studies should not only focus on classical outcomes as
MRI parameters, relapse activity, and disability progression.
Other symptoms found in MS have also been associated with
a poor vitamin D status, including presence of depressive
symptoms [23] and cognitive decline [24]. Including also
these parameters could provide a complete overview of the
impact of vitamin D supplementation in MS.
There are many diﬀerent opinions about vitamin D in
MS, ranging from scepticism to a ﬁrm belief in the new
panacea. These opinions reﬂect the current state of evidence:
there are a lot of indications for a therapeutic role of vitamin
D in MS, but these remain all circumstantial evidence.
Everyone will agree, however, that these indications provide
at least an excellent reason to develop well-designed clinical
trials on vitamin D supplementation in MS. Currently ﬁrst
clinical trials are starting up and will undoubtedly cast more
light on the issue.
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